revenue for Q4 2023, with the Company reporting $148.1M (US$97.1M1) of total product revenue, primarily generated from sales of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the United States, an increase of 11% on the prior quarter (Q3 2023) total revenue of $133.6M (US$87.2M2).
Growth in Illuccix hasnt petered out at all.
its growing
and 19% increase in dose volume.
gawd
cant complain there can we ....(someone will )
well done CB
i was praying for the magic $150. but hoping not to see and shortfalls. and you've delivered
noice
200% growth in 2023 - hello !?
and its not 200% from smalls ... its half a Billion dollars and growing
Ann: JP Morgan Healthcare Conference Presentation, page-3
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.18 |
Change
-0.140(0.76%) |
Mkt cap ! $6.076B | |||
| Open | High | Low | Value | Volume |
| $18.45 | $18.64 | $18.01 | $11.83M | 650.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1106 | $18.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.18 | 231 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |